Utilizing In Vitro and PBPK Tools to Link ADME Characteristics to Plasma Profiles: Case Example Nifedipine Immediate Release Formulation
One of the most prominent food-drug interactions is the inhibition of intestinal cytochrome P450 (CYP) 3A enzymes by grapefruit juice ingredients, and, as many drugs are metabolized via CYP 3A, this interaction can be of clinical importance. Calcium channel-blocking agents of the dihydropyridine typ...
Saved in:
| Published in | Journal of pharmaceutical sciences Vol. 102; no. 9; pp. 3205 - 3219 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken
Elsevier Inc
01.09.2013
Wiley Subscription Services, Inc., A Wiley Company Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-3549 1520-6017 1520-6017 |
| DOI | 10.1002/jps.23611 |
Cover
| Abstract | One of the most prominent food-drug interactions is the inhibition of intestinal cytochrome P450 (CYP) 3A enzymes by grapefruit juice ingredients, and, as many drugs are metabolized via CYP 3A, this interaction can be of clinical importance. Calcium channel-blocking agents of the dihydropyridine type, such as felodipine and nifedipine, are subject to extensive intestinal first pass metabolism via CYP 3A, thus resulting in significantly enhanced in vivo exposure of the drug when administered together with grapefruit juice. Physiologically based pharmacokinetic (PBPK) modeling was used to simulate pharmacokinetics of a nifedipine immediate release formulation following concomitant grapefruit juice ingestion, that is, after inhibition of small intestinal CYP 3A enzymes. For this purpose, detailed data about CYP 3A levels were collected from the literature and implemented into commercial PBPK software. As literature reports show that grapefruit juice (i) leads to a marked delay in gastric emptying, and (ii) rapidly lowers the levels of intestinal CYP 3A enzymes, inhibition of intestinal first pass metabolism following ingestion of grapefruit juice was simulated by altering the intestinal CYP 3A enzyme levels and simultaneously decelerating the gastric emptying rate. To estimate the in vivo dispersion and dissolution behavior of the formulation, dissolution tests in several media simulating both the fasted and fed state stomach and small intestine were conducted, and the results from the in vitro dissolution tests were used as input function to describe the in vivo dissolution of the drug. Plasma concentration-time profiles of the nifedipine immediate release formulation both with and without simultaneous CYP 3A inhibition were simulated, and the results were compared with data gathered from the literature. Using this approach, nifedipine plasma profiles could be simulated well both with and without enzyme inhibition. A reduction in small intestinal CYP 3A levels by 60% was found to yield the best results, with simulated nifedipine concentration-time profiles within 20% of the in vivo observed results. By additionally varying the dissolution input of the PBPK model, a link between the dissolution characteristics of the formulation and its in vivo performance could be established. |
|---|---|
| AbstractList | One of the most prominent food–drug interactions is the inhibition of intestinal cytochrome P450 (CYP) 3A enzymes by grapefruit juice ingredients, and, as many drugs are metabolized via CYP 3A, this interaction can be of clinical importance. Calcium channel‐blocking agents of the dihydropyridine type, such as felodipine and nifedipine, are subject to extensive intestinal first pass metabolism via CYP 3A, thus resulting in significantly enhanced in vivo exposure of the drug when administered together with grapefruit juice. Physiologically based pharmacokinetic (PBPK) modeling was used to simulate pharmacokinetics of a nifedipine immediate release formulation following concomitant grapefruit juice ingestion, that is, after inhibition of small intestinal CYP 3A enzymes. For this purpose, detailed data about CYP 3A levels were collected from the literature and implemented into commercial PBPK software. As literature reports show that grapefruit juice (i) leads to a marked delay in gastric emptying, and (ii) rapidly lowers the levels of intestinal CYP 3A enzymes, inhibition of intestinal first pass metabolism following ingestion of grapefruit juice was simulated by altering the intestinal CYP 3A enzyme levels and simultaneously decelerating the gastric emptying rate. To estimate the in vivo dispersion and dissolution behavior of the formulation, dissolution tests in several media simulating both the fasted and fed state stomach and small intestine were conducted, and the results from the in vitro dissolution tests were used as input function to describe the in vivo dissolution of the drug. Plasma concentration–time profiles of the nifedipine immediate release formulation both with and without simultaneous CYP 3A inhibition were simulated, and the results were compared with data gathered from the literature. Using this approach, nifedipine plasma profiles could be simulated well both with and without enzyme inhibition. A reduction in small intestinal CYP 3A levels by 60% was found to yield the best results, with simulated nifedipine concentration–time profiles within 20% of the in vivo observed results. By additionally varying the dissolution input of the PBPK model, a link between the dissolution characteristics of the formulation and its in vivo performance could be established. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:3205–3219, 2013 One of the most prominent food-drug interactions is the inhibition of intestinal cytochrome P450 (CYP) 3A enzymes by grapefruit juice ingredients, and, as many drugs are metabolized via CYP 3A, this interaction can be of clinical importance. Calcium channel-blocking agents of the dihydropyridine type, such as felodipine and nifedipine, are subject to extensive intestinal first pass metabolism via CYP 3A, thus resulting in significantly enhanced in vivo exposure of the drug when administered together with grapefruit juice. Physiologically based pharmacokinetic (PBPK) modeling was used to simulate pharmacokinetics of a nifedipine immediate release formulation following concomitant grapefruit juice ingestion, that is, after inhibition of small intestinal CYP 3A enzymes. For this purpose, detailed data about CYP 3A levels were collected from the literature and implemented into commercial PBPK software. As literature reports show that grapefruit juice (i) leads to a marked delay in gastric emptying, and (ii) rapidly lowers the levels of intestinal CYP 3A enzymes, inhibition of intestinal first pass metabolism following ingestion of grapefruit juice was simulated by altering the intestinal CYP 3A enzyme levels and simultaneously decelerating the gastric emptying rate. To estimate the in vivo dispersion and dissolution behavior of the formulation, dissolution tests in several media simulating both the fasted and fed state stomach and small intestine were conducted, and the results from the in vitro dissolution tests were used as input function to describe the in vivo dissolution of the drug. Plasma concentration-time profiles of the nifedipine immediate release formulation both with and without simultaneous CYP 3A inhibition were simulated, and the results were compared with data gathered from the literature. Using this approach, nifedipine plasma profiles could be simulated well both with and without enzyme inhibition. A reduction in small intestinal CYP 3A levels by 60% was found to yield the best results, with simulated nifedipine concentration-time profiles within 20% of the in vivo observed results. By additionally varying the dissolution input of the PBPK model, a link between the dissolution characteristics of the formulation and its in vivo performance could be established. One of the most prominent food-drug interactions is the inhibition of intestinal cytochrome P450 (CYP) 3A enzymes by grapefruit juice ingredients, and, as many drugs are metabolized via CYP 3A, this interaction can be of clinical importance. Calcium channel-blocking agents of the dihydropyridine type, such as felodipine and nifedipine, are subject to extensive intestinal first pass metabolism via CYP 3A, thus resulting in significantly enhanced in vivo exposure of the drug when administered together with grapefruit juice. Physiologically based pharmacokinetic (PBPK) modeling was used to simulate pharmacokinetics of a nifedipine immediate release formulation following concomitant grapefruit juice ingestion, that is, after inhibition of small intestinal CYP 3A enzymes. For this purpose, detailed data about CYP 3A levels were collected from the literature and implemented into commercial PBPK software. As literature reports show that grapefruit juice (i) leads to a marked delay in gastric emptying, and (ii) rapidly lowers the levels of intestinal CYP 3A enzymes, inhibition of intestinal first pass metabolism following ingestion of grapefruit juice was simulated by altering the intestinal CYP 3A enzyme levels and simultaneously decelerating the gastric emptying rate. To estimate the in vivo dispersion and dissolution behavior of the formulation, dissolution tests in several media simulating both the fasted and fed state stomach and small intestine were conducted, and the results from the in vitro dissolution tests were used as input function to describe the in vivo dissolution of the drug. Plasma concentration-time profiles of the nifedipine immediate release formulation both with and without simultaneous CYP 3A inhibition were simulated, and the results were compared with data gathered from the literature. Using this approach, nifedipine plasma profiles could be simulated well both with and without enzyme inhibition. A reduction in small intestinal CYP 3A levels by 60% was found to yield the best results, with simulated nifedipine concentration-time profiles within 20% of the in vivo observed results. By additionally varying the dissolution input of the PBPK model, a link between the dissolution characteristics of the formulation and its in vivo performance could be established.One of the most prominent food-drug interactions is the inhibition of intestinal cytochrome P450 (CYP) 3A enzymes by grapefruit juice ingredients, and, as many drugs are metabolized via CYP 3A, this interaction can be of clinical importance. Calcium channel-blocking agents of the dihydropyridine type, such as felodipine and nifedipine, are subject to extensive intestinal first pass metabolism via CYP 3A, thus resulting in significantly enhanced in vivo exposure of the drug when administered together with grapefruit juice. Physiologically based pharmacokinetic (PBPK) modeling was used to simulate pharmacokinetics of a nifedipine immediate release formulation following concomitant grapefruit juice ingestion, that is, after inhibition of small intestinal CYP 3A enzymes. For this purpose, detailed data about CYP 3A levels were collected from the literature and implemented into commercial PBPK software. As literature reports show that grapefruit juice (i) leads to a marked delay in gastric emptying, and (ii) rapidly lowers the levels of intestinal CYP 3A enzymes, inhibition of intestinal first pass metabolism following ingestion of grapefruit juice was simulated by altering the intestinal CYP 3A enzyme levels and simultaneously decelerating the gastric emptying rate. To estimate the in vivo dispersion and dissolution behavior of the formulation, dissolution tests in several media simulating both the fasted and fed state stomach and small intestine were conducted, and the results from the in vitro dissolution tests were used as input function to describe the in vivo dissolution of the drug. Plasma concentration-time profiles of the nifedipine immediate release formulation both with and without simultaneous CYP 3A inhibition were simulated, and the results were compared with data gathered from the literature. Using this approach, nifedipine plasma profiles could be simulated well both with and without enzyme inhibition. A reduction in small intestinal CYP 3A levels by 60% was found to yield the best results, with simulated nifedipine concentration-time profiles within 20% of the in vivo observed results. By additionally varying the dissolution input of the PBPK model, a link between the dissolution characteristics of the formulation and its in vivo performance could be established. One of the most prominent food-drug interactions is the inhibition of intestinal cytochrome P450 (CYP) 3A enzymes by grapefruit juice ingredients, and, as many drugs are metabolized via CYP 3A, this interaction can be of clinical importance. Calcium channel-blocking agents of the dihydropyridine type, such as felodipine and nifedipine, are subject to extensive intestinal first pass metabolism via CYP 3A, thus resulting in significantly enhanced in vivo exposure of the drug when administered together with grapefruit juice. Physiologically based pharmacokinetic (PBPK) modeling was used to simulate pharmacokinetics of a nifedipine immediate release formulation following concomitant grapefruit juice ingestion, that is, after inhibition of small intestinal CYP 3A enzymes. For this purpose, detailed data about CYP 3A levels were collected from the literature and implemented into commercial PBPK software. As literature reports show that grapefruit juice (i) leads to a marked delay in gastric emptying, and (ii) rapidly lowers the levels of intestinal CYP 3A enzymes, inhibition of intestinal first pass metabolism following ingestion of grapefruit juice was simulated by altering the intestinal CYP 3A enzyme levels and simultaneously decelerating the gastric emptying rate. To estimate the in vivo dispersion and dissolution behavior of the formulation, dissolution tests in several media simulating both the fasted and fed state stomach and small intestine were conducted, and the results from the in vitro dissolution tests were used as input function to describe the in vivo dissolution of the drug. Plasma concentration-time profiles of the nifedipine immediate release formulation both with and without simultaneous CYP 3A inhibition were simulated, and the results were compared with data gathered from the literature. Using this approach, nifedipine plasma profiles could be simulated well both with and without enzyme inhibition. A reduction in small intestinal CYP 3A levels by 60% was found to yield the best results, with simulated nifedipine concentration-time profiles within 20% of the in vivo observed results. By additionally varying the dissolution input of the PBPK model, a link between the dissolution characteristics of the formulation and its in vivo performance could be established. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:3205-3219, 2013 [PUBLICATION ABSTRACT] |
| Author | Willmann, Stefan Wagner, Christian Thelen, Kirstin Selen, Arzu Dressman, Jennifer B. |
| Author_xml | – sequence: 1 givenname: Christian surname: Wagner fullname: Wagner, Christian organization: Institute of Pharmaceutical Technology, Goethe University, 60438 Frankfurt am Main, Germany – sequence: 2 givenname: Kirstin surname: Thelen fullname: Thelen, Kirstin organization: Technology Package Computational Systems Biology, Bayer Technology Services GmbH, 51368 Leverkusen, Germany – sequence: 3 givenname: Stefan surname: Willmann fullname: Willmann, Stefan organization: Technology Package Computational Systems Biology, Bayer Technology Services GmbH, 51368 Leverkusen, Germany – sequence: 4 givenname: Arzu surname: Selen fullname: Selen, Arzu organization: Office of New Drug Quality Assessment/OPS/CDER, United States Food and Drug Administration, Silver Spring, Maryland 20993 – sequence: 5 givenname: Jennifer B. surname: Dressman fullname: Dressman, Jennifer B. email: dressman@em.uni-frankfurt.de organization: Institute of Pharmaceutical Technology, Goethe University, 60438 Frankfurt am Main, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23696038$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kUtvEzEUhS1URNPCgj-ALLGhi2n9yjzYlTSFQIAIWraW47kDDh57sB2g_AJ-Nm4em6qsbOl-59j3nCN04LwDhJ5SckoJYWerIZ4yXlL6AI3omJGiJLQ6QKM8YwUfi-YQHcW4IoSUZDx-hA4z3JSE1yP09zoZa_4Y9xXPHP5iUvBYuRYvXi3e4SvvbcTJ47lx3_H5xfspnnxTQekEwcRk9Ga4sCr2Ci-C74yF-BJPVAQ8_a36wQL-YDpozWAc4Fnf56tKgD-BhVvo0od-bVUy3j1GDztlIzzZncfo-nJ6NXlTzD--nk3O54XmTUULqphodFWLdkkYkEZ0NatLymi9rJpKVISVtGxFteRcV5WCZgxiqbpK17TjquX8GL3Y-g7B_1hDTLI3UYO1yoFfR0kFyynVlDUZfX4HXfl1cPl3maKNKDkTJFPPdtR6mfeTQzC9Cjdyn3EGzraADj7GAJ3UJm12TkEZKymRty3K3KLctJgVJ3cUe9P72J37rxz-zf9B-Xbxea_gWwXkmH8aCDJqA07nbgLoJFtv7nnnH_Hfu2U |
| CODEN | JPMSAE |
| CitedBy_id | crossref_primary_10_1016_j_ejpb_2016_06_010 crossref_primary_10_1208_s12248_018_0231_8 crossref_primary_10_1016_j_ejpb_2016_07_013 crossref_primary_10_1016_j_ejpb_2018_08_004 crossref_primary_10_1016_j_ejps_2019_04_026 crossref_primary_10_1021_acs_molpharmaceut_7b00286 crossref_primary_10_1111_jphp_12411 crossref_primary_10_3389_fphar_2021_630904 crossref_primary_10_1002_cpt_2968 crossref_primary_10_1016_j_xphs_2016_06_015 crossref_primary_10_1002_jps_24162 crossref_primary_10_1002_jps_24560 crossref_primary_10_1016_j_ijpharm_2023_123634 crossref_primary_10_1021_acs_molpharmaceut_6b01155 crossref_primary_10_1021_acs_molpharmaceut_3c00170 crossref_primary_10_1111_jphp_12618 crossref_primary_10_1002_psp4_12260 crossref_primary_10_1016_j_ejpb_2018_07_003 crossref_primary_10_1208_s12248_020_00508_2 crossref_primary_10_1208_s12249_020_01683_3 crossref_primary_10_1002_bdd_2360 crossref_primary_10_1016_j_ejpb_2015_05_015 crossref_primary_10_1016_j_ejps_2017_03_011 crossref_primary_10_1155_2019_7537618 |
| Cites_doi | 10.1016/j.ejpb.2008.10.019 10.1620/tjem.148.421 10.1124/dmd.105.008672 10.1002/j.1552-4604.1983.tb02720.x 10.1111/j.1365-2125.1986.tb02954.x 10.1016/0140-6736(91)90872-M 10.1002/jps.22026 10.1172/JCI119439 10.1111/j.1365-2125.1995.tb04534.x 10.1016/j.ejps.2005.08.011 10.2165/00003088-200847100-00003 10.1111/j.1365-2125.1988.tb03307.x 10.1002/jps.22825 10.1016/S0090-9556(24)15229-4 10.1208/s12248-008-9061-4 10.1016/S0022-3565(24)37149-6 10.1021/jm030999b 10.1016/S0140-6736(95)90700-9 10.1016/j.ejpb.2010.10.012 10.1007/s002280050092 10.1053/cp.1999.v66.100453001 10.1093/ajcn/83.5.1097 10.1016/j.ejpb.2009.05.009 10.1016/j.ejpb.2012.05.008 10.1016/S0169-409X(02)00013-3 10.2165/00003495-198325020-00002 10.1046/j.1365-2125.1998.00764.x 10.2165/00003088-199222060-00002 10.1021/mp034006h 10.1016/j.ejpb.2010.06.003 10.1016/j.amjhyper.2005.11.003 10.1016/0009-9236(95)90188-4 10.1023/A:1016212804288 10.1038/clpt.1984.105 10.1517/17425255.1.1.159 10.1023/B:PHAM.0000003373.72652.c0 10.1023/A:1012160419520 10.1016/0009-9236(95)90032-2 10.1111/j.1365-2125.1988.tb05256.x 10.1002/cbdv.200900054 10.1007/s002280050296 10.1124/jpet.106.106013 10.1007/s10928-007-9053-5 10.1111/j.1365-2125.1990.tb03691.x 10.1002/jps.20212 10.1111/j.1365-2125.1984.tb02569.x 10.1016/S1478-5382(03)02342-4 10.1016/S0009-9236(97)90189-2 10.1208/s12248-008-9079-7 10.1208/s12249-008-9161-6 10.1038/clpt.1987.110 10.2165/00003088-199426020-00002 10.1016/S0022-3565(25)11138-5 10.1111/j.1365-2125.1986.tb02936.x 10.1016/S0031-6997(24)01402-9 10.1211/jpp.61.07.0008 10.1016/S0928-0987(02)00132-X 10.1016/S0090-9556(25)08440-5 10.4065/75.9.933 10.1007/s11095-008-9569-4 10.1007/BF00192360 10.1016/0009-9236(95)90068-3 10.1016/j.ejpb.2005.03.002 10.2165/00003088-198712010-00002 10.1002/jps.22726 10.1016/0006-2952(84)90165-5 10.1111/j.1365-2710.2004.00618.x 10.1208/s12248-010-9250-9 10.1136/gut.12.8.611 |
| ContentType | Journal Article |
| Copyright | 2013 Wiley Periodicals, Inc. and the American Pharmacists Association Copyright © 2013 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2013 Wiley Periodicals, Inc. and the American Pharmacists Association – notice: Copyright © 2013 Wiley Periodicals, Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7QP 7QR 7TK 7U7 8FD C1K FR3 P64 RC3 7X8 |
| DOI | 10.1002/jps.23611 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Genetics Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1520-6017 |
| EndPage | 3219 |
| ExternalDocumentID | 3042436851 23696038 10_1002_jps_23611 JPS23611 S0022354915309540 |
| Genre | article Research Support, U.S. Gov't, P.H.S Journal Article |
| GroupedDBID | --- -~X .3N .GA .GJ .Y3 05W 0R~ 10A 1CY 1L6 1OC 1ZS 31~ 33P 36B 3O- 3WU 4.4 457 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 A8Z AAEVG AAHHS AAIAV AAKUH AALRI AAOIN AAONW AAXUO AAYOK AAZKR ABCQN ABEML ABFRF ABIJN ABJNI ABMAC ABOCM ABPVW ABWRO ACBWZ ACCFJ ACGFO ACGFS ACIWK ACPRK ACSCC ACXME ACXQS ADBBV ADIZJ AEEZP AEFWE AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFRAH AFTJW AFZJQ AGHFR AI. AITUG AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMRAJ ATUGU AZBYB BAFTC BDRZF BFHJK BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DU5 E3Z EBD EBS EJD EMB EMOBN ESTFP F00 F01 F04 F5P FDB FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HHY HHZ HOLLA HVGLF HX~ HZ~ IX1 J0M JPC KQQ L7B LAW LC2 LC3 LH4 LP6 LP7 LSO LW6 M41 M6Q MK0 MK4 N04 N05 N9A NF~ NNB O66 O9- P2P P2X P4D Q.N Q11 QB0 QRW R.K RNS ROL RWI RX1 RYL SSZ SUPJJ SV3 UB1 UKR UNMZH V2E V8K VH1 W8V W99 WBFHL WH7 WIB WJL WQJ WRC WUP WWP WYUIH XG1 XPP XV2 Y6R YCJ ZE2 ZGI ZXP ~IA ~WT AANHP ACRPL ACYXJ ADNMO ADVLN AFJKZ AKRWK OIG AAMMB AAYWO AAYXX ACVFH ADCNI AEFGJ AEUPX AFPUW AGCQF AGQPQ AGXDD AIDQK AIDYY AIGII AKBMS AKYEP APXCP CITATION CGR CUY CVF ECM EIF NPM VXZ Z5M 7QO 7QP 7QR 7TK 7U7 8FD C1K EFKBS FR3 P64 RC3 7X8 |
| ID | FETCH-LOGICAL-c3971-1a249c784db02e094f82861218b7974702616d47b33c77ae95e4baf7c81f3ad33 |
| IEDL.DBID | DR2 |
| ISSN | 0022-3549 1520-6017 |
| IngestDate | Sat Sep 27 19:30:23 EDT 2025 Wed Aug 13 11:05:58 EDT 2025 Wed Feb 19 01:55:55 EST 2025 Sun Jul 06 05:06:04 EDT 2025 Thu Apr 24 22:59:09 EDT 2025 Wed Jan 22 17:09:50 EST 2025 Fri Feb 23 02:30:59 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | absorption bioavailability computational ADME dissolution pharmacokinetics first-pass metabolism quality by design (QbD) cytochrome P450 drug metabolizing enzymes |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2013 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3971-1a249c784db02e094f82861218b7974702616d47b33c77ae95e4baf7c81f3ad33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-2 content type line 23 |
| PMID | 23696038 |
| PQID | 1419463240 |
| PQPubID | 1006386 |
| PageCount | 15 |
| ParticipantIDs | proquest_miscellaneous_1420608129 proquest_journals_1419463240 pubmed_primary_23696038 crossref_citationtrail_10_1002_jps_23611 crossref_primary_10_1002_jps_23611 wiley_primary_10_1002_jps_23611_JPS23611 elsevier_sciencedirect_doi_10_1002_jps_23611 |
| PublicationCentury | 2000 |
| PublicationDate | September 2013 |
| PublicationDateYYYYMMDD | 2013-09-01 |
| PublicationDate_xml | – month: 09 year: 2013 text: September 2013 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken |
| PublicationPlace_xml | – name: Hoboken – name: United States – name: Washington |
| PublicationTitle | Journal of pharmaceutical sciences |
| PublicationTitleAlternate | J Pharm Sci |
| PublicationYear | 2013 |
| Publisher | Elsevier Inc Wiley Subscription Services, Inc., A Wiley Company Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Wiley Subscription Services, Inc., A Wiley Company – name: Elsevier Limited |
| References | Kleinbloesem, van Brummelen, Breimer (bb0350) 1987; 12 Galetin, Houston (bb0360) 2006; 318 The United States Pharmacopeial Convention (bb0300) 2008 Paine, Hart, Ludington, Haining, Rettie, Zeldin (bb0010) 2006; 34 Hukkinen, Varhe, Olkkola, Neuvonen (bb0095) 1995; 58 Thelen, Coboeken, Willmann, Burghaus, Dressman, Lippert (bb0305) 2011; 100 Willmann, Schmitt, Keldenich, Dressman (bb0320) 2003; 20 Lilja, Kivisto, Neuvonen (bb0110) 1999; 66 Ducharme, Warbasse, Edwards (bb0100) 1995; 57 Waller, Renwick, Gruchy, George (bb0235) 1984; 18 Foster, Hamann, Richards, Bryant, Graves, McAllister (bb0200) 1983; 23 Juenemann, Jantratid, Wagner, Reppas, Vertzoni, Dressman (bb0135) 2011; 77 Bailey, Arnold, Spence (bb0025) 1994; 26 Okumu, DiMaso, Lobenberg (bb0155) 2009; 72 Raemsch, Sommer (bb0255) 1983; 5 Sigusch, Hippius, Henschel, Kaufmann, Hoffmann (bb0075) 1994; 49 Grass, Sinko (bb0130) 2002; 54 Paine, Khalighi, Fisher, Shen, Kunze, Marsh, Perkins, Thummel (bb0365) 1997; 283 Miniscalco, Lundahl, Regardh, Edgar, Eriksson (bb0120) 1992; 261 Zhang, Lionberger, Davit, Yu (bb0195) 2011; 13 Heading, Tothill, Laidlaw, Shearman (bb0375) 1971; 12 Marston, Polli (bb0390) 1997; 14 Odou, Ferrari, Barthelemy, Brique, Lhermitte, Vincent, Libersa, Robert (bb0055) 2005; 30 Vertzoni, Dressman, Butler, Hempenstall, Reppas (bb0285) 2005; 60 Schmiedlin-Ren, Edwards, Fitzsimmons, He, Lown, Woster, Rahman, Thummel, Fisher, Hollenberg, Watkins (bb0065) 1997; 25 . Kane, Lipsky (bb0040) 2000; 75 McAllister (bb0220) 1982; 4 Lin, Chiba, Baillie (bb0400) 1999; 51 Kesisoglou, Wu (bb0145) 2008; 10 Kasim, Whitehouse, Ramachandran, Bermejo, Lennernas, Hussain, Junginger, Stavchansky, Midha, Shah, Amidon (bb0355) 2004; 1 Thelen, Jantratid, Dressman, Lippert, Willmann (bb0175) 2010; 99 Shono, Jantratid, Janssen, Kesisoglou, Mao, Vertzoni, Reppas, Dressman (bb0170) 2009; 73 Willmann, Edington, Kleine-Besten, JantratidE, Dressman (bb0185) 2009; 61 Sica (bb0070) 2006; 19 Klein, Shah (bb0295) 2008; 9 Kates (bb0260) 1983; 25 Petring, Adelhoj, Ibsen, Poulsen (bb0380) 1986; 22 Berger (bb0370) 1969; 404 Reitberg, Love, Quercia, Zinny (bb0270) 1987; 42 James (bb0115) 1995 Robertson, Waller, Renwick, George (bb0230) 1988; 25 Dressman, Thelen, Jantratid (bb0005) 2008; 47 Paine, Widmer, Hart, Pusek, Beavers, Criss, Brown, Thomas, Watkins (bb0125) 2006; 83 Kelly, O’Malley (bb0345) 1992; 22 Clifford, Adams, Murray, Taylor, Wilkins, Boobis, Davies (bb0080) 1997; 52 Zhang, Dunbar, Ostrowska, Zeisloft, Yang, Kaminsky (bb0015) 1999; 27 Kuentz, Nick, Parrott, Rothlisberger (bb0150) 2006; 27 Glomme, Marz, Dressman (bb0290) 2005; 94 Willmann, Lippert, Sevestre, Solodenko, Fois, Schmitt (bb0340) 2003; 1 Rashid, Martin, Clarke, Waller, Renwick, George (bb0060) 1995; 40 German prescribers information. Accessed November, 2012, at Imai, Abe, Sasaki, Nihei, Sekino, Yoshinaga (bb0205) 1986; 148 Kleinbloesem, van Brummelen, Faber, Danhof, Vermeulen, Breimer (bb0210) 1984; 33 Parrott, Lukacova, Fraczkiewicz, Bolger (bb0165) 2009; 11 Amidon, Lennernas, Shah, Crison (bb0275) 1995; 12 Lown, Bailey, Fontana, Janardan, Adair, Fortlage, Brown, Guo, Watkins (bb0045) 1997; 99 Willmann, Thelen, Becker, Dressman, Lippert (bb0190) 2010; 76 Jantratid, Janssen, Reppas, Dressman (bb0280) 2008; 25 Willmann, Schmitt, Keldenich, Lippert, Dressman (bb0325) 2004; 47 Parrott, Lave (bb0160) 2002; 17 Valentin (bb0330) 2002; 32 Wagner, Jantratid, Kesisoglou, Vertzoni, Reppas, Dressman (bb0180) 2012; 82 Keldenich (bb0140) 2009; 6 Eichelbaum (bb0250) 1980; 3 Challenor, Waller, Gruchy, Renwick, George, McMurdo, McEwen (bb0395) 1986; 22 Spence (bb0085) 1997; 61 Lundahl, Regardh, Edgar, Johnsson (bb0050) 1995; 49 Pasanisi, Meredith, Reid (bb0265) 1985; 5 Lown, Kolars, Thummel, Barnett, Kunze, Wrighton, Watkins (bb0020) 1994; 22 Kleinbloesem, van Brummelen, van de Linde, Voogd, Breimer (bb0215) 1984; 35 Bode, Brendel, Ahr, Fuhr, Harder, Staib (bb0245) 1996; 50 Willmann, Hohn, Edginton, Sevestre, Solodenko, Weiss, Lippert, Schmitt (bb0335) 2007; 34 Petring, Flachs (bb0385) 1990; 29 Renwick, Robertson, Macklin, Challenor, Waller, George (bb0225) 1988; 25 Bailey, Malcolm, Arnold, Spence (bb0030) 1998; 46 Willmann, Lippert, Schmitt (bb0315) 2005; 1 Kupferschmidt, Ha, Ziegler, Meier, Krahenbuhl (bb0090) 1995; 58 Yee, Stanley, Pessa, Dalla Costa, Beltz, Ruiz, Lowenthal (bb0105) 1995; 345 Thelen, Coboeken, Willmann, Dressman, Lippert (bb0310) 2012; 101 Bailey, Spence, Munoz, Arnold (bb0035) 1991; 337 2002; 17 2010; 99 2006; 34 2002; 54 1983; 5 2008; 9 1994; 22 2011; 13 1994; 26 2005; 60 2004; 1 1969; 404 2007; 34 1998; 46 2009; 11 1987; 42 1986; 148 1997; 99 1997; 52 2006; 27 1971; 12 1997; 14 1982; 4 2008; 25 2005; 30 1984; 18 1999; 51 2003; 1 1983; 25 1983; 23 2012; 82 2010; 76 1987; 12 2006; 318 1997; 61 2012; 101 1992; 261 1985; 5 2009; 61 1995; 58 1995; 57 2004; 47 1999; 27 1997; 25 1995; 12 2002; 32 1996; 50 2008 1999; 66 2011; 77 2006; 19 1995 1994; 49 2008; 10 1991; 337 1995; 40 2009; 73 2006; 83 1995; 49 2009; 72 1997; 283 1986; 22 1990; 29 1988; 25 1984; 33 2000; 75 1984; 35 1980; 3 2008; 47 1995; 345 2005; 1 2009; 6 2005; 94 1992; 22 2003; 20 2011; 100 Kelly (10.1002/jps.23611_bb0345) 1992; 22 10.1002/jps.23611_bb0240 Glomme (10.1002/jps.23611_bb0290) 2005; 94 James (10.1002/jps.23611_bb0115) 1995 Thelen (10.1002/jps.23611_bb0175) 2010; 99 Foster (10.1002/jps.23611_bb0200) 1983; 23 Willmann (10.1002/jps.23611_bb0190) 2010; 76 Miniscalco (10.1002/jps.23611_bb0120) 1992; 261 Hukkinen (10.1002/jps.23611_bb0095) 1995; 58 Klein (10.1002/jps.23611_bb0295) 2008; 9 Thelen (10.1002/jps.23611_bb0305) 2011; 100 Thelen (10.1002/jps.23611_bb0310) 2012; 101 Willmann (10.1002/jps.23611_bb0325) 2004; 47 Kleinbloesem (10.1002/jps.23611_bb0215) 1984; 35 Kasim (10.1002/jps.23611_bb0355) 2004; 1 Paine (10.1002/jps.23611_bb0010) 2006; 34 Wagner (10.1002/jps.23611_bb0180) 2012; 82 Willmann (10.1002/jps.23611_bb0320) 2003; 20 Petring (10.1002/jps.23611_bb0385) 1990; 29 Spence (10.1002/jps.23611_bb0085) 1997; 61 Eichelbaum (10.1002/jps.23611_bb0250) 1980; 3 Kupferschmidt (10.1002/jps.23611_bb0090) 1995; 58 Challenor (10.1002/jps.23611_bb0395) 1986; 22 Zhang (10.1002/jps.23611_bb0015) 1999; 27 Willmann (10.1002/jps.23611_bb0185) 2009; 61 Ducharme (10.1002/jps.23611_bb0100) 1995; 57 Reitberg (10.1002/jps.23611_bb0270) 1987; 42 Heading (10.1002/jps.23611_bb0375) 1971; 12 Kuentz (10.1002/jps.23611_bb0150) 2006; 27 McAllister (10.1002/jps.23611_bb0220) 1982; 4 Sica (10.1002/jps.23611_bb0070) 2006; 19 Bailey (10.1002/jps.23611_bb0035) 1991; 337 Imai (10.1002/jps.23611_bb0205) 1986; 148 Paine (10.1002/jps.23611_bb0125) 2006; 83 Lown (10.1002/jps.23611_bb0020) 1994; 22 Parrott (10.1002/jps.23611_bb0160) 2002; 17 Paine (10.1002/jps.23611_bb0365) 1997; 283 Lilja (10.1002/jps.23611_bb0110) 1999; 66 Clifford (10.1002/jps.23611_bb0080) 1997; 52 Shono (10.1002/jps.23611_bb0170) 2009; 73 Vertzoni (10.1002/jps.23611_bb0285) 2005; 60 Bode (10.1002/jps.23611_bb0245) 1996; 50 Pasanisi (10.1002/jps.23611_bb0265) 1985; 5 Odou (10.1002/jps.23611_bb0055) 2005; 30 Juenemann (10.1002/jps.23611_bb0135) 2011; 77 Okumu (10.1002/jps.23611_bb0155) 2009; 72 Kleinbloesem (10.1002/jps.23611_bb0210) 1984; 33 Lundahl (10.1002/jps.23611_bb0050) 1995; 49 Keldenich (10.1002/jps.23611_bb0140) 2009; 6 Zhang (10.1002/jps.23611_bb0195) 2011; 13 The United States Pharmacopeial Convention (10.1002/jps.23611_bb0300) 2008 Berger (10.1002/jps.23611_bb0370) 1969; 404 Lin (10.1002/jps.23611_bb0400) 1999; 51 Valentin (10.1002/jps.23611_bb0330) 2002; 32 Willmann (10.1002/jps.23611_bb0315) 2005; 1 Petring (10.1002/jps.23611_bb0380) 1986; 22 Bailey (10.1002/jps.23611_bb0025) 1994; 26 Galetin (10.1002/jps.23611_bb0360) 2006; 318 Yee (10.1002/jps.23611_bb0105) 1995; 345 Amidon (10.1002/jps.23611_bb0275) 1995; 12 Raemsch (10.1002/jps.23611_bb0255) 1983; 5 Renwick (10.1002/jps.23611_bb0225) 1988; 25 Bailey (10.1002/jps.23611_bb0030) 1998; 46 Kates (10.1002/jps.23611_bb0260) 1983; 25 Willmann (10.1002/jps.23611_bb0335) 2007; 34 Schmiedlin-Ren (10.1002/jps.23611_bb0065) 1997; 25 Kesisoglou (10.1002/jps.23611_bb0145) 2008; 10 Waller (10.1002/jps.23611_bb0235) 1984; 18 Dressman (10.1002/jps.23611_bb0005) 2008; 47 Jantratid (10.1002/jps.23611_bb0280) 2008; 25 Willmann (10.1002/jps.23611_bb0340) 2003; 1 Rashid (10.1002/jps.23611_bb0060) 1995; 40 Kane (10.1002/jps.23611_bb0040) 2000; 75 Robertson (10.1002/jps.23611_bb0230) 1988; 25 Kleinbloesem (10.1002/jps.23611_bb0350) 1987; 12 Sigusch (10.1002/jps.23611_bb0075) 1994; 49 Parrott (10.1002/jps.23611_bb0165) 2009; 11 Marston (10.1002/jps.23611_bb0390) 1997; 14 Lown (10.1002/jps.23611_bb0045) 1997; 99 Grass (10.1002/jps.23611_bb0130) 2002; 54 |
| References_xml | – volume: 52 start-page: 311 year: 1997 end-page: 315 ident: bb0080 article-title: The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice publication-title: Eur J Clin Pharmacol – reference: German prescribers information. Accessed November, 2012, at: – volume: 58 start-page: 20 year: 1995 end-page: 28 ident: bb0090 article-title: Interaction between grapefruit juice and midazolam in humans publication-title: Clin Pharmacol Ther – volume: 99 start-page: 2899 year: 2010 end-page: 2904 ident: bb0175 article-title: Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing publication-title: J Pharm Sci – volume: 12 start-page: 413 year: 1995 end-page: 420 ident: bb0275 article-title: A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability publication-title: Pharm Res – volume: 40 start-page: 51 year: 1995 end-page: 58 ident: bb0060 article-title: Factors affecting the absolute bioavailability of nifedipine publication-title: Br J Clin Pharmacol – volume: 23 start-page: 161 year: 1983 end-page: 170 ident: bb0200 article-title: Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects publication-title: J Clin Pharmacol – volume: 27 start-page: 91 year: 2006 end-page: 99 ident: bb0150 article-title: A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study publication-title: Eur J Pharm Sci – volume: 318 start-page: 1220 year: 2006 end-page: 1229 ident: bb0360 article-title: Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: Impact on prediction of first-pass metabolism publication-title: J Pharmacol Exp Ther – volume: 18 start-page: 951 year: 1984 end-page: 954 ident: bb0235 article-title: The first pass metabolism of nifedipine in man publication-title: Br J Clin Pharmacol – volume: 72 start-page: 91 year: 2009 end-page: 98 ident: bb0155 article-title: Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products publication-title: Eur J Pharm Biopharm – volume: 54 start-page: 433 year: 2002 end-page: 451 ident: bb0130 article-title: Physiologically based pharmacokinetic simulation modelling publication-title: Adv Drug Deliv Rev – volume: 51 start-page: 135 year: 1999 end-page: 158 ident: bb0400 article-title: Is the role of the small intestine in first-pass metabolism overemphasized? publication-title: Pharmacol Rev – volume: 25 start-page: 1228 year: 1997 end-page: 1233 ident: bb0065 article-title: Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins publication-title: Drug Metab Dispos – volume: 49 start-page: 61 year: 1995 end-page: 67 ident: bb0050 article-title: Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects publication-title: Eur J Clin Pharmacol – volume: 30 start-page: 153 year: 2005 end-page: 158 ident: bb0055 article-title: Grapefruit juice-nifedipine interaction: Possible involvement of several mechanisms publication-title: J Clin Pharm Ther – volume: 5 start-page: 63 year: 1985 end-page: 66 ident: bb0265 article-title: Pharmacokinetics of nifedipine publication-title: Int J Clin Pharmacol Res – volume: 94 start-page: 1 year: 2005 end-page: 16 ident: bb0290 article-title: Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities publication-title: J Pharm Sci – volume: 34 start-page: 401 year: 2007 end-page: 431 ident: bb0335 article-title: Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs publication-title: J Pharmacokinet Pharmacodyn – volume: 47 start-page: 655 year: 2008 end-page: 667 ident: bb0005 article-title: Towards quantitative prediction of oral drug absorption publication-title: Clin Pharmacokinet – volume: 11 start-page: 45 year: 2009 end-page: 53 ident: bb0165 article-title: Predicting pharmacokinetics of drugs using physiologically based modeling—Application to food effects publication-title: AAPS J – volume: 9 start-page: 1179 year: 2008 end-page: 1184 ident: bb0295 article-title: A standardized mini paddle apparatus as an alternative to the standard paddle publication-title: AAPS PharmSciTech – volume: 47 start-page: 4022 year: 2004 end-page: 4031 ident: bb0325 article-title: A physiological model for the estimation of the fraction dose absorbed in humans publication-title: J Med Chem – volume: 99 start-page: 2545 year: 1997 end-page: 2553 ident: bb0045 article-title: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression publication-title: J Clin Invest – volume: 337 start-page: 268 year: 1991 end-page: 269 ident: bb0035 article-title: Interaction of citrus juices with felodipine and nifedipine publication-title: Lancet – volume: 32 start-page: 5 year: 2002 end-page: 265 ident: bb0330 article-title: Basic anatomical and physiological data for use in radiological protection: Reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals 2002. ICRP Publication 89 publication-title: Ann ICRP – volume: 13 start-page: 59 year: 2011 end-page: 71 ident: bb0195 article-title: Utility of physiologically based absorption modeling in implementing quality by design in drug development publication-title: AAPS J – volume: 61 start-page: 891 year: 2009 end-page: 899 ident: bb0185 article-title: Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: Inter-individual variability of cimetidine absorption publication-title: J Pharm Pharmacol – volume: 1 start-page: 85 year: 2004 end-page: 96 ident: bb0355 article-title: Molecular properties of WHO essential drugs and provisional biopharmaceutical classification publication-title: Mol Pharm – volume: 29 start-page: 703 year: 1990 end-page: 708 ident: bb0385 article-title: Inter- and intrasubject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption publication-title: Br J Clin Pharmacol – volume: 283 start-page: 1552 year: 1997 end-page: 1562 ident: bb0365 article-title: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism publication-title: J Pharmacol Exp Ther – volume: 148 start-page: 421 year: 1986 end-page: 438 ident: bb0205 article-title: Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients publication-title: Tohoku J Exp Med – volume: 25 start-page: 701 year: 1988 end-page: 708 ident: bb0225 article-title: The pharmacokinetics of oral nifedipine—A population study publication-title: Br J Clin Pharmacol – volume: 261 start-page: 1195 year: 1992 end-page: 1199 ident: bb0120 article-title: Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice publication-title: J Pharmacol Exp Ther – volume: 60 start-page: 413 year: 2005 end-page: 417 ident: bb0285 article-title: Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds publication-title: Eur J Pharm Biopharm – volume: 404 start-page: 1 year: 1969 end-page: 51 ident: bb0370 article-title: Studies on the gastric emptying mechanism in healthy persons and patients after partial gastrectomy publication-title: Acta Chir Scand Suppl – volume: 3 start-page: 13 year: 1980 end-page: 17 ident: bb0250 article-title: Clinical pharmacokinetics of calcium ion antagonists publication-title: Clin Invest Med – volume: 345 start-page: 955 year: 1995 end-page: 956 ident: bb0105 article-title: Effect of grapefruit juice on blood cyclosporin concentration publication-title: Lancet – volume: 77 start-page: 257 year: 2011 end-page: 264 ident: bb0135 article-title: Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles publication-title: Eur J Pharm Biopharm – volume: 17 start-page: 51 year: 2002 end-page: 61 ident: bb0160 article-title: Prediction of intestinal absorption: Comparative assessment of GASTROPLUS and IDEA publication-title: Eur J Pharm Sci – volume: 82 start-page: 127 year: 2012 end-page: 138 ident: bb0180 article-title: Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model publication-title: Eur J Pharm Biopharm – volume: 83 start-page: 1097 year: 2006 end-page: 1105 ident: bb0125 article-title: A furanocoumarin-free grapefruit juice establishes fura-nocoumarins as the mediators of the grapefruit juice-felodipine interaction publication-title: Am J Clin Nutr – year: 2008 ident: bb0300 article-title: The United States Pharmacopeia 31 – volume: 20 start-page: 1766 year: 2003 end-page: 1771 ident: bb0320 article-title: A physiologic model for simulating gastrointestinal flow and drug absorption in rats publication-title: Pharm Res – volume: 46 start-page: 101 year: 1998 end-page: 110 ident: bb0030 article-title: Grapefruit juice-drug interactions publication-title: Br J Clin Pharmacol – volume: 61 start-page: 395 year: 1997 end-page: 400 ident: bb0085 article-title: Drug interactions with grapefruit: Whose responsibility is it to warn the public? publication-title: Clin Pharmacol Ther – volume: 58 start-page: 127 year: 1995 end-page: 131 ident: bb0095 article-title: Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice publication-title: Clin Pharmacol Ther – volume: 12 start-page: 611 year: 1971 end-page: 615 ident: bb0375 article-title: An evaluation of indium DTPA chelate in the measurement of gastric emptying by scintiscanning publication-title: Gut – volume: 57 start-page: 485 year: 1995 end-page: 491 ident: bb0100 article-title: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice publication-title: Clin Pharmacol Ther – volume: 1 start-page: 159 year: 2005 end-page: 168 ident: bb0315 article-title: From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools publication-title: Expert Opin Drug Metab Toxicol – volume: 19 start-page: 768 year: 2006 end-page: 773 ident: bb0070 article-title: Interaction of grapefruit juice and calcium channel blockers publication-title: Am J Hypertens – volume: 5 start-page: II18 year: 1983 end-page: II24 ident: bb0255 article-title: Pharmacokinetics and metabolism of nifedipine publication-title: Hypertension – volume: 22 start-page: 565 year: 1986 end-page: 570 ident: bb0395 article-title: The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine publication-title: Br J Clin Pharmacol – volume: 25 start-page: 113 year: 1983 end-page: 124 ident: bb0260 article-title: Calcium antagonists. Pharmacokinetic properties publication-title: Drugs – volume: 42 start-page: 72 year: 1987 end-page: 75 ident: bb0270 article-title: Effect of food on nifedipine pharmacokinetics publication-title: Clin Pharmacol Ther – volume: 101 start-page: 1267 year: 2012 end-page: 1280 ident: bb0310 article-title: Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: Extension to describe performance of solid dosage forms publication-title: J Pharm Sci – volume: 22 start-page: 947 year: 1994 end-page: 955 ident: bb0020 article-title: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test publication-title: Drug Metab Dispos – volume: 6 start-page: 2000 year: 2009 end-page: 2013 ident: bb0140 article-title: Measurement and prediction of oral absorption publication-title: Chem Biodivers – volume: 12 start-page: 12 year: 1987 end-page: 29 ident: bb0350 article-title: Nifedipine. Relationship between pharmacokinetics and pharmacodynamics publication-title: Clin Pharmacokinet – volume: 76 start-page: 83 year: 2010 end-page: 94 ident: bb0190 article-title: Mechanism-based prediction of particle size-dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs publication-title: Eur J Pharm Biopharm – volume: 75 start-page: 933 year: 2000 end-page: 942 ident: bb0040 article-title: Drug-grapefruit juice interactions publication-title: Mayo Clin Proc – volume: 4 start-page: S340 year: 1982 end-page: S345 ident: bb0220 article-title: Clinical pharmacokinetics of calcium channel antagonists publication-title: J Cardiovasc Pharmacol – start-page: 5 year: 1995 end-page: 6 ident: bb0115 article-title: Grapefruit juice and saquinavir publication-title: AIDS Treat News – volume: 10 start-page: 516 year: 2008 end-page: 525 ident: bb0145 article-title: Understanding the effect of API properties on bioavailability through absorption modeling publication-title: AAPS J – volume: 73 start-page: 107 year: 2009 end-page: 114 ident: bb0170 article-title: Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling publication-title: Eur J Pharm Biopharm – volume: 26 start-page: 91 year: 1994 end-page: 98 ident: bb0025 article-title: Grapefruit juice and drugs. How significant is the interaction? publication-title: Clin Pharmacokinet – volume: 50 start-page: 195 year: 1996 end-page: 201 ident: bb0245 article-title: Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine publication-title: Eur J Clin Pharmacol – volume: 22 start-page: 659 year: 1986 end-page: 662 ident: bb0380 article-title: The relationship between gastric emptying of semisolids and paracetamol absorption publication-title: Br J Clin Pharmacol – reference: . – volume: 33 start-page: 3721 year: 1984 end-page: 3724 ident: bb0210 article-title: Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man publication-title: Biochem Pharmacol – volume: 66 start-page: 118 year: 1999 end-page: 127 ident: bb0110 article-title: Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin publication-title: Clin Pharmacol Ther – volume: 34 start-page: 880 year: 2006 end-page: 886 ident: bb0010 article-title: The human intestinal cytochrome P450 “pie” publication-title: Drug Metab Dispos – volume: 14 start-page: 1363 year: 1997 end-page: 1369 ident: bb0390 article-title: Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence publication-title: Pharm Res – volume: 25 start-page: 297 year: 1988 end-page: 305 ident: bb0230 article-title: Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine publication-title: Br J Clin Pharmacol – volume: 25 start-page: 1663 year: 2008 end-page: 1676 ident: bb0280 article-title: Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update publication-title: Pharm Res – volume: 22 start-page: 416 year: 1992 end-page: 433 ident: bb0345 article-title: Clinical pharmacokinetics of calcium antagonists publication-title: An update. Clin Pharmacokinet – volume: 35 start-page: 742 year: 1984 end-page: 749 ident: bb0215 article-title: Nifedipine: Kinetics and dynamics in healthy subjects publication-title: Clin Pharmacol Ther – volume: 27 start-page: 804 year: 1999 end-page: 809 ident: bb0015 article-title: Characterization of human small intestinal cytochromes P-450 publication-title: Drug Metab Dispos – volume: 49 start-page: 522 year: 1994 end-page: 524 ident: bb0075 article-title: Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation publication-title: Pharmazie – volume: 100 start-page: 5324 year: 2011 end-page: 5345 ident: bb0305 article-title: Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: Oral solutions publication-title: J Pharm Sci – volume: 1 start-page: 121 year: 2003 end-page: 124 ident: bb0340 article-title: PK-Sim(R): A physiologically based pharmacokinetic “whole-body” model publication-title: Biosilico – volume: 73 start-page: 107 issue: 1 year: 2009 end-page: 114 article-title: Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling publication-title: Eur J Pharm Biopharm – volume: 51 start-page: 135 issue: 2 year: 1999 end-page: 158 article-title: Is the role of the small intestine in first‐pass metabolism overemphasized? publication-title: Pharmacol Rev – volume: 75 start-page: 933 issue: 9 year: 2000 end-page: 942 article-title: Drug‐grapefruit juice interactions publication-title: Mayo Clin Proc – volume: 25 start-page: 701 issue: 6 year: 1988 end-page: 708 article-title: The pharmacokinetics of oral nifedipine—A population study publication-title: Br J Clin Pharmacol – volume: 49 start-page: 522 issue: 7 year: 1994 end-page: 524 article-title: Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation publication-title: Pharmazie – volume: 61 start-page: 891 issue: 7 year: 2009 end-page: 899 article-title: Whole‐body physiologically based pharmacokinetic population modelling of oral drug administration: Inter‐individual variability of cimetidine absorption publication-title: J Pharm Pharmacol – volume: 47 start-page: 4022 issue: 16 year: 2004 end-page: 4031 article-title: A physiological model for the estimation of the fraction dose absorbed in humans publication-title: J Med Chem – volume: 25 start-page: 1228 issue: 11 year: 1997 end-page: 1233 article-title: Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism‐based inactivation by furanocoumarins publication-title: Drug Metab Dispos – volume: 12 start-page: 611 issue: 8 year: 1971 end-page: 615 article-title: An evaluation of indium DTPA chelate in the measurement of gastric emptying by scintiscanning publication-title: Gut – volume: 33 start-page: 3721 issue: 22 year: 1984 end-page: 3724 article-title: Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man publication-title: Biochem Pharmacol – volume: 22 start-page: 565 issue: 5 year: 1986 end-page: 570 article-title: The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine publication-title: Br J Clin Pharmacol – volume: 72 start-page: 91 issue: 1 year: 2009 end-page: 98 article-title: Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products publication-title: Eur J Pharm Biopharm – volume: 13 start-page: 59 issue: 1 year: 2011 end-page: 71 article-title: Utility of physiologically based absorption modeling in implementing quality by design in drug development publication-title: AAPS J – volume: 40 start-page: 51 issue: 1 year: 1995 end-page: 58 article-title: Factors affecting the absolute bioavailability of nifedipine publication-title: Br J Clin Pharmacol – volume: 1 start-page: 121 issue: 4 year: 2003 end-page: 124 article-title: PK‐Sim(R): A physiologically based pharmacokinetic “whole‐body” model publication-title: Biosilico – volume: 345 start-page: 955 issue: 8955 year: 1995 end-page: 956 article-title: Effect of grapefruit juice on blood cyclosporin concentration publication-title: Lancet – volume: 34 start-page: 401 issue: 3 year: 2007 end-page: 431 article-title: Development of a physiology‐based whole‐body population model for assessing the influence of individual variability on the pharmacokinetics of drugs publication-title: J Pharmacokinet Pharmacodyn – volume: 18 start-page: 951 issue: 6 year: 1984 end-page: 954 article-title: The first pass metabolism of nifedipine in man publication-title: Br J Clin Pharmacol – volume: 25 start-page: 1663 issue: 7 year: 2008 end-page: 1676 article-title: Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update publication-title: Pharm Res – volume: 404 start-page: 1 year: 1969 end-page: 51 article-title: Studies on the gastric emptying mechanism in healthy persons and patients after partial gastrectomy publication-title: Acta Chir Scand Suppl – volume: 57 start-page: 485 issue: 5 year: 1995 end-page: 491 article-title: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice publication-title: Clin Pharmacol Ther – volume: 49 start-page: 61 issue: 1–2 year: 1995 end-page: 67 article-title: Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects publication-title: Eur J Clin Pharmacol – volume: 12 start-page: 12 issue: 1 year: 1987 end-page: 29 article-title: Nifedipine. Relationship between pharmacokinetics and pharmacodynamics publication-title: Clin Pharmacokinet – volume: 76 start-page: 83 issue: 1 year: 2010 end-page: 94 article-title: Mechanism‐based prediction of particle size‐dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs publication-title: Eur J Pharm Biopharm – volume: 32 start-page: 5 issue: 3–4 year: 2002 end-page: 265 article-title: Valentin J. 2002. Basic anatomical and physiological data for use in radiological protection: Reference values. A report of age‐ and gender‐related differences in the anatomical and physiological characteristics of reference individuals publication-title: Ann ICRP – volume: 318 start-page: 1220 issue: 3 year: 2006 end-page: 1229 article-title: Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: Impact on prediction of first‐pass metabolism publication-title: J Pharmacol Exp Ther – volume: 14 start-page: 1363 issue: 10 year: 1997 end-page: 1369 article-title: Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence publication-title: Pharm Res – volume: 337 start-page: 268 issue: 8736 year: 1991 end-page: 269 article-title: Interaction of citrus juices with felodipine and nifedipine publication-title: Lancet – volume: 27 start-page: 91 issue: 1 year: 2006 end-page: 99 article-title: A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study publication-title: Eur J Pharm Sci – year: 2008 – volume: 29 start-page: 703 issue: 6 year: 1990 end-page: 708 article-title: Inter‐ and intrasubject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption publication-title: Br J Clin Pharmacol – volume: 148 start-page: 421 issue: 4 year: 1986 end-page: 438 article-title: Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients publication-title: Tohoku J Exp Med – volume: 60 start-page: 413 issue: 3 year: 2005 end-page: 417 article-title: Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds publication-title: Eur J Pharm Biopharm – volume: 6 start-page: 2000 issue: 11 year: 2009 end-page: 2013 article-title: Measurement and prediction of oral absorption publication-title: Chem Biodivers – volume: 11 start-page: 45 issue: 1 year: 2009 end-page: 53 article-title: Predicting pharmacokinetics of drugs using physiologically based modeling—Application to food effects publication-title: AAPS J – volume: 9 start-page: 1179 issue: 4 year: 2008 end-page: 1184 article-title: A standardized mini paddle apparatus as an alternative to the standard paddle publication-title: AAPS PharmSciTech – volume: 50 start-page: 195 issue: 3 year: 1996 end-page: 201 article-title: Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C‐ and 12C‐nifedipine publication-title: Eur J Clin Pharmacol – volume: 42 start-page: 72 issue: 1 year: 1987 end-page: 75 article-title: Effect of food on nifedipine pharmacokinetics publication-title: Clin Pharmacol Ther – volume: 1 start-page: 85 issue: 1 year: 2004 end-page: 96 article-title: Molecular properties of WHO essential drugs and provisional biopharmaceutical classification publication-title: Mol Pharm – volume: 35 start-page: 742 issue: 6 year: 1984 end-page: 749 article-title: Nifedipine: Kinetics and dynamics in healthy subjects publication-title: Clin Pharmacol Ther – volume: 26 start-page: 91 issue: 2 year: 1994 end-page: 98 article-title: Grapefruit juice and drugs. How significant is the interaction? publication-title: Clin Pharmacokinet – volume: 17 start-page: 51 issue: 1–2 year: 2002 end-page: 61 article-title: Prediction of intestinal absorption: Comparative assessment of GASTROPLUS and IDEA publication-title: Eur J Pharm Sci – volume: 5 start-page: I18 issue: 4 Pt 2 year: 1983 end-page: 24 article-title: Pharmacokinetics and metabolism of nifedipine publication-title: Hypertension – volume: 1 start-page: 159 issue: 1 year: 2005 end-page: 168 article-title: From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools publication-title: Expert Opin Drug Metab Toxicol – volume: 20 start-page: 1766 issue: 11 year: 2003 end-page: 1771 article-title: A physiologic model for simulating gastrointestinal flow and drug absorption in rats publication-title: Pharm Res – volume: 4( start-page: S340 issue: Suppl 3) year: 1982 end-page: S345 article-title: Clinical pharmacokinetics of calcium channel antagonists publication-title: J Cardiovasc Pharmacol – volume: 61 start-page: 395 issue: 4 year: 1997 end-page: 400 article-title: Drug interactions with grapefruit: Whose responsibility is it to warn the public? publication-title: Clin Pharmacol Ther – volume: 22 start-page: 947 issue: 6 year: 1994 end-page: 955 article-title: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test publication-title: Drug Metab Dispos – volume: 27 start-page: 804 issue: 7 year: 1999 end-page: 809 article-title: Characterization of human small intestinal cytochromes P‐450 publication-title: Drug Metab Dispos – volume: 25 start-page: 297 issue: 3 year: 1988 end-page: 305 article-title: Age‐related changes in the pharmacokinetics and pharmacodynamics of nifedipine publication-title: Br J Clin Pharmacol – volume: 3 start-page: 13 issue: 1–2 year: 1980 end-page: 17 article-title: Clinical pharmacokinetics of calcium ion antagonists publication-title: Clin Invest Med – volume: 46 start-page: 101 issue: 2 year: 1998 end-page: 110 article-title: Grapefruit juice‐drug interactions publication-title: Br J Clin Pharmacol – volume: 52 start-page: 311 issue: 4 year: 1997 end-page: 315 article-title: The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice publication-title: Eur J Clin Pharmacol – volume: 23 start-page: 161 issue: 4 year: 1983 end-page: 170 article-title: Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects publication-title: J Clin Pharmacol – volume: 283 start-page: 1552 issue: 3 year: 1997 end-page: 1562 article-title: Characterization of interintestinal and intraintestinal variations in human CYP3A‐dependent metabolism publication-title: J Pharmacol Exp Ther – volume: 34 start-page: 880 issue: 5 year: 2006 end-page: 886 article-title: The human intestinal cytochrome P450 “pie” publication-title: Drug Metab Dispos – volume: 22 start-page: 416 issue: 6 year: 1992 end-page: 433 article-title: Clinical pharmacokinetics of calcium antagonists. An update publication-title: Clin Pharmacokinet – volume: 30 start-page: 153 issue: 2 year: 2005 end-page: 158 article-title: Grapefruit juice‐nifedipine interaction: Possible involvement of several mechanisms publication-title: J Clin Pharm Ther – volume: 58 start-page: 127 issue: 2 year: 1995 end-page: 131 article-title: Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice publication-title: Clin Pharmacol Ther – volume: 83 start-page: 1097 issue: 5 year: 2006 end-page: 1105 article-title: A furanocoumarin‐free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice‐felodipine interaction publication-title: Am J Clin Nutr – volume: 25 start-page: 113 issue: 2 year: 1983 end-page: 124 article-title: Calcium antagonists. Pharmacokinetic properties publication-title: Drugs – volume: 10 start-page: 516 issue: 4 year: 2008 end-page: 525 article-title: Understanding the effect of API properties on bioavailability through absorption modeling publication-title: AAPS J – volume: 261 start-page: 1195 issue: 3 year: 1992 end-page: 1199 article-title: Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice publication-title: J Pharmacol Exp Ther – volume: 101 start-page: 1267 issue: 3 year: 2012 end-page: 1280 article-title: Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: Extension to describe performance of solid dosage forms publication-title: J Pharm Sci – volume: 82 start-page: 127 issue: 1 year: 2012 end-page: 138 article-title: Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model publication-title: Eur J Pharm Biopharm – volume: 94 start-page: 1 issue: 1 year: 2005 end-page: 16 article-title: Comparison of a miniaturized shake‐flask solubility method with automated potentiometric acid/base titrations and calculated solubilities publication-title: J Pharm Sci – start-page: 5 year: 1995 end-page: 6 article-title: Grapefruit juice and saquinavir publication-title: AIDS Treat News – volume: 99 start-page: 2545 issue: 10 year: 1997 end-page: 2553 article-title: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression publication-title: J Clin Invest – volume: 22 start-page: 659 issue: 6 year: 1986 end-page: 662 article-title: The relationship between gastric emptying of semisolids and paracetamol absorption publication-title: Br J Clin Pharmacol – volume: 77 start-page: 257 issue: 2 year: 2011 end-page: 264 article-title: Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles publication-title: Eur J Pharm Biopharm – volume: 100 start-page: 5324 issue: 12 year: 2011 end-page: 5345 article-title: Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: Oral solutions publication-title: J Pharm Sci – volume: 19 start-page: 768 issue: 7 year: 2006 end-page: 773 article-title: Interaction of grapefruit juice and calcium channel blockers publication-title: Am J Hypertens – volume: 66 start-page: 118 issue: 2 year: 1999 end-page: 127 article-title: Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin publication-title: Clin Pharmacol Ther – volume: 99 start-page: 2899 issue: 6 year: 2010 end-page: 2904 article-title: Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing publication-title: J Pharm Sci – volume: 54 start-page: 433 issue: 3 year: 2002 end-page: 451 article-title: Physiologically based pharmacokinetic simulation modelling publication-title: Adv Drug Deliv Rev – volume: 12 start-page: 413 issue: 3 year: 1995 end-page: 420 article-title: A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability publication-title: Pharm Res – volume: 5 start-page: 63 issue: 1 year: 1985 end-page: 66 article-title: Pharmacokinetics of nifedipine publication-title: Int J Clin Pharmacol Res – volume: 58 start-page: 20 issue: 1 year: 1995 end-page: 28 article-title: Interaction between grapefruit juice and midazolam in humans publication-title: Clin Pharmacol Ther – volume: 47 start-page: 655 issue: 10 year: 2008 end-page: 667 article-title: Towards quantitative prediction of oral drug absorption publication-title: Clin Pharmacokinet – volume: 72 start-page: 91 issue: 1 year: 2009 ident: 10.1002/jps.23611_bb0155 article-title: Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2008.10.019 – volume: 148 start-page: 421 issue: 4 year: 1986 ident: 10.1002/jps.23611_bb0205 article-title: Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients publication-title: Tohoku J Exp Med doi: 10.1620/tjem.148.421 – volume: 34 start-page: 880 issue: 5 year: 2006 ident: 10.1002/jps.23611_bb0010 article-title: The human intestinal cytochrome P450 “pie” publication-title: Drug Metab Dispos doi: 10.1124/dmd.105.008672 – volume: 23 start-page: 161 issue: 4 year: 1983 ident: 10.1002/jps.23611_bb0200 article-title: Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects publication-title: J Clin Pharmacol doi: 10.1002/j.1552-4604.1983.tb02720.x – volume: 3 start-page: 13 issue: 1-2 year: 1980 ident: 10.1002/jps.23611_bb0250 article-title: Clinical pharmacokinetics of calcium ion antagonists publication-title: Clin Invest Med – volume: 22 start-page: 659 issue: 6 year: 1986 ident: 10.1002/jps.23611_bb0380 article-title: The relationship between gastric emptying of semisolids and paracetamol absorption publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1986.tb02954.x – volume: 337 start-page: 268 issue: 8736 year: 1991 ident: 10.1002/jps.23611_bb0035 article-title: Interaction of citrus juices with felodipine and nifedipine publication-title: Lancet doi: 10.1016/0140-6736(91)90872-M – volume: 49 start-page: 522 issue: 7 year: 1994 ident: 10.1002/jps.23611_bb0075 article-title: Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation publication-title: Pharmazie – volume: 99 start-page: 2899 issue: 6 year: 2010 ident: 10.1002/jps.23611_bb0175 article-title: Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing publication-title: J Pharm Sci doi: 10.1002/jps.22026 – volume: 5 start-page: 63 issue: 1 year: 1985 ident: 10.1002/jps.23611_bb0265 article-title: Pharmacokinetics of nifedipine publication-title: Int J Clin Pharmacol Res – volume: 99 start-page: 2545 issue: 10 year: 1997 ident: 10.1002/jps.23611_bb0045 article-title: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression publication-title: J Clin Invest doi: 10.1172/JCI119439 – volume: 40 start-page: 51 issue: 1 year: 1995 ident: 10.1002/jps.23611_bb0060 article-title: Factors affecting the absolute bioavailability of nifedipine publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1995.tb04534.x – volume: 27 start-page: 91 issue: 1 year: 2006 ident: 10.1002/jps.23611_bb0150 article-title: A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2005.08.011 – volume: 47 start-page: 655 issue: 10 year: 2008 ident: 10.1002/jps.23611_bb0005 article-title: Towards quantitative prediction of oral drug absorption publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200847100-00003 – volume: 4 start-page: S340 issue: Suppl 3 year: 1982 ident: 10.1002/jps.23611_bb0220 article-title: Clinical pharmacokinetics of calcium channel antagonists publication-title: J Cardiovasc Pharmacol – volume: 25 start-page: 297 issue: 3 year: 1988 ident: 10.1002/jps.23611_bb0230 article-title: Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1988.tb03307.x – volume: 101 start-page: 1267 issue: 3 year: 2012 ident: 10.1002/jps.23611_bb0310 article-title: Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: Extension to describe performance of solid dosage forms publication-title: J Pharm Sci doi: 10.1002/jps.22825 – volume: 27 start-page: 804 issue: 7 year: 1999 ident: 10.1002/jps.23611_bb0015 article-title: Characterization of human small intestinal cytochromes P-450 publication-title: Drug Metab Dispos doi: 10.1016/S0090-9556(24)15229-4 – volume: 10 start-page: 516 issue: 4 year: 2008 ident: 10.1002/jps.23611_bb0145 article-title: Understanding the effect of API properties on bioavailability through absorption modeling publication-title: AAPS J doi: 10.1208/s12248-008-9061-4 – volume: 404 start-page: 1 year: 1969 ident: 10.1002/jps.23611_bb0370 article-title: Studies on the gastric emptying mechanism in healthy persons and patients after partial gastrectomy publication-title: Acta Chir Scand Suppl – volume: 25 start-page: 1228 issue: 11 year: 1997 ident: 10.1002/jps.23611_bb0065 article-title: Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins publication-title: Drug Metab Dispos – volume: 283 start-page: 1552 issue: 3 year: 1997 ident: 10.1002/jps.23611_bb0365 article-title: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)37149-6 – volume: 47 start-page: 4022 issue: 16 year: 2004 ident: 10.1002/jps.23611_bb0325 article-title: A physiological model for the estimation of the fraction dose absorbed in humans publication-title: J Med Chem doi: 10.1021/jm030999b – volume: 345 start-page: 955 issue: 8955 year: 1995 ident: 10.1002/jps.23611_bb0105 article-title: Effect of grapefruit juice on blood cyclosporin concentration publication-title: Lancet doi: 10.1016/S0140-6736(95)90700-9 – volume: 77 start-page: 257 issue: 2 year: 2011 ident: 10.1002/jps.23611_bb0135 article-title: Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2010.10.012 – volume: 50 start-page: 195 issue: 3 year: 1996 ident: 10.1002/jps.23611_bb0245 article-title: Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280050092 – volume: 66 start-page: 118 issue: 2 year: 1999 ident: 10.1002/jps.23611_bb0110 article-title: Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin publication-title: Clin Pharmacol Ther doi: 10.1053/cp.1999.v66.100453001 – volume: 5 start-page: II18 issue: 4 Pt 2 year: 1983 ident: 10.1002/jps.23611_bb0255 article-title: Pharmacokinetics and metabolism of nifedipine publication-title: Hypertension – volume: 83 start-page: 1097 issue: 5 year: 2006 ident: 10.1002/jps.23611_bb0125 article-title: A furanocoumarin-free grapefruit juice establishes fura-nocoumarins as the mediators of the grapefruit juice-felodipine interaction publication-title: Am J Clin Nutr doi: 10.1093/ajcn/83.5.1097 – volume: 73 start-page: 107 issue: 1 year: 2009 ident: 10.1002/jps.23611_bb0170 article-title: Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2009.05.009 – volume: 82 start-page: 127 issue: 1 year: 2012 ident: 10.1002/jps.23611_bb0180 article-title: Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2012.05.008 – volume: 54 start-page: 433 issue: 3 year: 2002 ident: 10.1002/jps.23611_bb0130 article-title: Physiologically based pharmacokinetic simulation modelling publication-title: Adv Drug Deliv Rev doi: 10.1016/S0169-409X(02)00013-3 – volume: 25 start-page: 113 issue: 2 year: 1983 ident: 10.1002/jps.23611_bb0260 article-title: Calcium antagonists. Pharmacokinetic properties publication-title: Drugs doi: 10.2165/00003495-198325020-00002 – volume: 46 start-page: 101 issue: 2 year: 1998 ident: 10.1002/jps.23611_bb0030 article-title: Grapefruit juice-drug interactions publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1998.00764.x – volume: 22 start-page: 416 issue: 6 year: 1992 ident: 10.1002/jps.23611_bb0345 article-title: Clinical pharmacokinetics of calcium antagonists publication-title: An update. Clin Pharmacokinet doi: 10.2165/00003088-199222060-00002 – volume: 1 start-page: 85 issue: 1 year: 2004 ident: 10.1002/jps.23611_bb0355 article-title: Molecular properties of WHO essential drugs and provisional biopharmaceutical classification publication-title: Mol Pharm doi: 10.1021/mp034006h – volume: 76 start-page: 83 issue: 1 year: 2010 ident: 10.1002/jps.23611_bb0190 article-title: Mechanism-based prediction of particle size-dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2010.06.003 – volume: 19 start-page: 768 issue: 7 year: 2006 ident: 10.1002/jps.23611_bb0070 article-title: Interaction of grapefruit juice and calcium channel blockers publication-title: Am J Hypertens doi: 10.1016/j.amjhyper.2005.11.003 – volume: 58 start-page: 127 issue: 2 year: 1995 ident: 10.1002/jps.23611_bb0095 article-title: Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice publication-title: Clin Pharmacol Ther doi: 10.1016/0009-9236(95)90188-4 – volume: 12 start-page: 413 issue: 3 year: 1995 ident: 10.1002/jps.23611_bb0275 article-title: A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability publication-title: Pharm Res doi: 10.1023/A:1016212804288 – volume: 35 start-page: 742 issue: 6 year: 1984 ident: 10.1002/jps.23611_bb0215 article-title: Nifedipine: Kinetics and dynamics in healthy subjects publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1984.105 – volume: 1 start-page: 159 issue: 1 year: 2005 ident: 10.1002/jps.23611_bb0315 article-title: From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425255.1.1.159 – volume: 20 start-page: 1766 issue: 11 year: 2003 ident: 10.1002/jps.23611_bb0320 article-title: A physiologic model for simulating gastrointestinal flow and drug absorption in rats publication-title: Pharm Res doi: 10.1023/B:PHAM.0000003373.72652.c0 – volume: 14 start-page: 1363 issue: 10 year: 1997 ident: 10.1002/jps.23611_bb0390 article-title: Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence publication-title: Pharm Res doi: 10.1023/A:1012160419520 – volume: 57 start-page: 485 issue: 5 year: 1995 ident: 10.1002/jps.23611_bb0100 article-title: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice publication-title: Clin Pharmacol Ther doi: 10.1016/0009-9236(95)90032-2 – volume: 25 start-page: 701 issue: 6 year: 1988 ident: 10.1002/jps.23611_bb0225 article-title: The pharmacokinetics of oral nifedipine—A population study publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1988.tb05256.x – volume: 6 start-page: 2000 issue: 11 year: 2009 ident: 10.1002/jps.23611_bb0140 article-title: Measurement and prediction of oral absorption publication-title: Chem Biodivers doi: 10.1002/cbdv.200900054 – volume: 52 start-page: 311 issue: 4 year: 1997 ident: 10.1002/jps.23611_bb0080 article-title: The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280050296 – volume: 318 start-page: 1220 issue: 3 year: 2006 ident: 10.1002/jps.23611_bb0360 article-title: Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: Impact on prediction of first-pass metabolism publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.106.106013 – start-page: 5 issue: no 235 year: 1995 ident: 10.1002/jps.23611_bb0115 article-title: Grapefruit juice and saquinavir publication-title: AIDS Treat News – year: 2008 ident: 10.1002/jps.23611_bb0300 – volume: 34 start-page: 401 issue: 3 year: 2007 ident: 10.1002/jps.23611_bb0335 article-title: Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-007-9053-5 – volume: 29 start-page: 703 issue: 6 year: 1990 ident: 10.1002/jps.23611_bb0385 article-title: Inter- and intrasubject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1990.tb03691.x – volume: 32 start-page: 5 issue: 3-4 year: 2002 ident: 10.1002/jps.23611_bb0330 article-title: Basic anatomical and physiological data for use in radiological protection: Reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals 2002. ICRP Publication 89 publication-title: Ann ICRP – volume: 94 start-page: 1 issue: 1 year: 2005 ident: 10.1002/jps.23611_bb0290 article-title: Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities publication-title: J Pharm Sci doi: 10.1002/jps.20212 – volume: 18 start-page: 951 issue: 6 year: 1984 ident: 10.1002/jps.23611_bb0235 article-title: The first pass metabolism of nifedipine in man publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1984.tb02569.x – volume: 1 start-page: 121 issue: 4 year: 2003 ident: 10.1002/jps.23611_bb0340 article-title: PK-Sim(R): A physiologically based pharmacokinetic “whole-body” model publication-title: Biosilico doi: 10.1016/S1478-5382(03)02342-4 – volume: 61 start-page: 395 issue: 4 year: 1997 ident: 10.1002/jps.23611_bb0085 article-title: Drug interactions with grapefruit: Whose responsibility is it to warn the public? publication-title: Clin Pharmacol Ther doi: 10.1016/S0009-9236(97)90189-2 – volume: 11 start-page: 45 issue: 1 year: 2009 ident: 10.1002/jps.23611_bb0165 article-title: Predicting pharmacokinetics of drugs using physiologically based modeling—Application to food effects publication-title: AAPS J doi: 10.1208/s12248-008-9079-7 – volume: 9 start-page: 1179 issue: 4 year: 2008 ident: 10.1002/jps.23611_bb0295 article-title: A standardized mini paddle apparatus as an alternative to the standard paddle publication-title: AAPS PharmSciTech doi: 10.1208/s12249-008-9161-6 – volume: 42 start-page: 72 issue: 1 year: 1987 ident: 10.1002/jps.23611_bb0270 article-title: Effect of food on nifedipine pharmacokinetics publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1987.110 – volume: 26 start-page: 91 issue: 2 year: 1994 ident: 10.1002/jps.23611_bb0025 article-title: Grapefruit juice and drugs. How significant is the interaction? publication-title: Clin Pharmacokinet doi: 10.2165/00003088-199426020-00002 – volume: 261 start-page: 1195 issue: 3 year: 1992 ident: 10.1002/jps.23611_bb0120 article-title: Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)11138-5 – volume: 22 start-page: 565 issue: 5 year: 1986 ident: 10.1002/jps.23611_bb0395 article-title: The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1986.tb02936.x – ident: 10.1002/jps.23611_bb0240 – volume: 51 start-page: 135 issue: 2 year: 1999 ident: 10.1002/jps.23611_bb0400 article-title: Is the role of the small intestine in first-pass metabolism overemphasized? publication-title: Pharmacol Rev doi: 10.1016/S0031-6997(24)01402-9 – volume: 61 start-page: 891 issue: 7 year: 2009 ident: 10.1002/jps.23611_bb0185 article-title: Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: Inter-individual variability of cimetidine absorption publication-title: J Pharm Pharmacol doi: 10.1211/jpp.61.07.0008 – volume: 17 start-page: 51 issue: 1-2 year: 2002 ident: 10.1002/jps.23611_bb0160 article-title: Prediction of intestinal absorption: Comparative assessment of GASTROPLUS and IDEA publication-title: Eur J Pharm Sci doi: 10.1016/S0928-0987(02)00132-X – volume: 22 start-page: 947 issue: 6 year: 1994 ident: 10.1002/jps.23611_bb0020 article-title: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test publication-title: Drug Metab Dispos doi: 10.1016/S0090-9556(25)08440-5 – volume: 75 start-page: 933 issue: 9 year: 2000 ident: 10.1002/jps.23611_bb0040 article-title: Drug-grapefruit juice interactions publication-title: Mayo Clin Proc doi: 10.4065/75.9.933 – volume: 25 start-page: 1663 issue: 7 year: 2008 ident: 10.1002/jps.23611_bb0280 article-title: Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update publication-title: Pharm Res doi: 10.1007/s11095-008-9569-4 – volume: 49 start-page: 61 issue: 1-2 year: 1995 ident: 10.1002/jps.23611_bb0050 article-title: Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00192360 – volume: 58 start-page: 20 issue: 1 year: 1995 ident: 10.1002/jps.23611_bb0090 article-title: Interaction between grapefruit juice and midazolam in humans publication-title: Clin Pharmacol Ther doi: 10.1016/0009-9236(95)90068-3 – volume: 60 start-page: 413 issue: 3 year: 2005 ident: 10.1002/jps.23611_bb0285 article-title: Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2005.03.002 – volume: 12 start-page: 12 issue: 1 year: 1987 ident: 10.1002/jps.23611_bb0350 article-title: Nifedipine. Relationship between pharmacokinetics and pharmacodynamics publication-title: Clin Pharmacokinet doi: 10.2165/00003088-198712010-00002 – volume: 100 start-page: 5324 issue: 12 year: 2011 ident: 10.1002/jps.23611_bb0305 article-title: Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: Oral solutions publication-title: J Pharm Sci doi: 10.1002/jps.22726 – volume: 33 start-page: 3721 issue: 22 year: 1984 ident: 10.1002/jps.23611_bb0210 article-title: Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man publication-title: Biochem Pharmacol doi: 10.1016/0006-2952(84)90165-5 – volume: 30 start-page: 153 issue: 2 year: 2005 ident: 10.1002/jps.23611_bb0055 article-title: Grapefruit juice-nifedipine interaction: Possible involvement of several mechanisms publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2004.00618.x – volume: 13 start-page: 59 issue: 1 year: 2011 ident: 10.1002/jps.23611_bb0195 article-title: Utility of physiologically based absorption modeling in implementing quality by design in drug development publication-title: AAPS J doi: 10.1208/s12248-010-9250-9 – volume: 12 start-page: 611 issue: 8 year: 1971 ident: 10.1002/jps.23611_bb0375 article-title: An evaluation of indium DTPA chelate in the measurement of gastric emptying by scintiscanning publication-title: Gut doi: 10.1136/gut.12.8.611 |
| SSID | ssj0006055 |
| Score | 2.2560024 |
| Snippet | One of the most prominent food-drug interactions is the inhibition of intestinal cytochrome P450 (CYP) 3A enzymes by grapefruit juice ingredients, and, as many... One of the most prominent food–drug interactions is the inhibition of intestinal cytochrome P450 (CYP) 3A enzymes by grapefruit juice ingredients, and, as many... |
| SourceID | proquest pubmed crossref wiley elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3205 |
| SubjectTerms | absorption Beverages - analysis bioavailability Calcium Channel Blockers - administration & dosage Calcium Channel Blockers - blood Calcium Channel Blockers - chemistry Calcium Channel Blockers - metabolism Citrus paradisi - metabolism computational ADME Computer Simulation Cytochrome P-450 CYP3A - metabolism Cytochrome P-450 CYP3A Inhibitors cytochrome P450 dissolution drug metabolizing enzymes first-pass metabolism Food-Drug Interactions Humans Models, Biological Nifedipine - administration & dosage Nifedipine - blood Nifedipine - chemistry Nifedipine - metabolism pharmacokinetics quality by design (QbD) Solubility |
| Title | Utilizing In Vitro and PBPK Tools to Link ADME Characteristics to Plasma Profiles: Case Example Nifedipine Immediate Release Formulation |
| URI | https://dx.doi.org/10.1002/jps.23611 https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjps.23611 https://www.ncbi.nlm.nih.gov/pubmed/23696038 https://www.proquest.com/docview/1419463240 https://www.proquest.com/docview/1420608129 |
| Volume | 102 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1La9wwEMeHkFMufT82Tcu0lNDDemPLz21PaR6ElBTTZiGHgpEsGdxu7CX2hiafoB-7M34taRMovRiBxyDbI81_bOk3AG8zT1AgmmZWILSyvMAPLalVakXat2UQSVca_t5x8jk4mnnHZ_7ZGnzo98K0fIjhgxuPjGa-5gEuVbWzgoZ-X1QTJodw6uO4AXPz97-s0FEk0_2BFE5JUE8VssXOcOVdsehvrXlTujax5_A-fOt73S45-TFZ1mqSXv8BdPzP23oA9zpNirutEz2ENVM8gu24hVpfjfF0tUerGuM2xivc9dVj-DWr83l-TSEQ8wIv8_qiRFlojD_Gn7Auy3lFR-Qfxbi7f3KA6U1ENJ9ckIQ_l9jVD6_e4x7FVjQ_JaOLkVffaC6xbTA_b3a61Aa51gsbsebuKpA9gdnhwenekdXVd7BSUkGO5UjK_dIw8rSyhaE8M-M97Q6JDhVymsPpYaC9ULluGobSTH3jKZmFaeRkrtSu-xTWi7IwzwEj5SulHHJIEnjaDqhhi4xsfAa-qWAE7_o3naQd_JxrcMyTFtssEnruSfPcR_BmMF20xI_bjMa9uySdVGklSEJv9Dbzrd6lkm6OqCjpcqYe0_LtEbweTtPo5l82sjDlkm0EeTKJsOkInrWuOHRKcClG243o3hqHuru3yXH8tWls_rvpC9gQTeUPXk63Bev1xdK8JP1Vq1fNQPsN2XUs6A |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5V5QAXWt5pCwwIVRzi1G87iEsprULbVBYkUi9otetdS25TO6odRPsL-NnM-BUVWglxsVbasbSPmZ1v9vENY-8S10ZHNEwM31bScH0vMISSsREqzxR-KByhab9jfOKPpu7hqXe6wj62b2Fqfohuw40so1qvycBpQ3pnyRp6Ni8GRB2Csc-96nyOINHXJXkUAnWv4wrHMKjlFTLtne7Xu7zR32jzJnitvM_BGvvetru-dHI-WJRyEF__Qen4vx1bZw8bWAq7tR49Yis6e8y2o5rX-qoPk-UzraIP2xAtGa-vnrBf0zKdpdfoBSHN4EdaXuYgMgXRp-gIyjyfFfgFOiuG3c_jfYhvskRT5RxR_IWAJoV48QH20L2C_imIvRjoAo6iLNsa0ovqsUupgdK9kBDB7iYJ2VM2Pdif7I2MJsWDESMQsgxLYPgXB6GrpGlrDDUTetZuIe6QAUU6FCH6yg2k48RBIPTQ064USRCHVuII5TjP2GqWZ_oFg1B6UkoLdRIxnjJ9LJh2gjIecb5Jv8fet1PN44b_nNJwzHjN3GxzHHdejXuPve1E5zXpx21C_VZfeINWahTCcUpvE99qdYo3y0SBcZc1dIkw3-yxN101Gjid2ohM5wuSsVGVEYcNe-x5rYtdo2zKxmg6Ifat0qi7W8sPo29VYePfRV-z-6PJ-Jgffzk52mQP7CoRCN2u22Kr5eVCv0Q4VspXldX9Bo2_MQY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELaqIiFeuI8tBQaEKh4228Q5F55K21VpaRVBV-oDkmXHjhS6TVZNFtH-An42M7lWhVZCvESWPJF8jD3f2J5vGHubehwN0Ti1Aq6V5QV-aEmtEivSvi2DSLrS0HnH4VGwN_X2T_yTFfahi4Vp-CH6AzdaGfV-TQt8rtPNJWno93k5IuYQdH1ueQGaSUJEX5bcUYjT_Z4qHL2gjlbI5pv9rzcZo7_B5lXsWhufyT32rWt28-bkdLSo1Ci5_IPR8T_7dZ_dbUEpbDVa9ICtmPwh24gbVuuLIRwvg7TKIWxAvOS7vnjEfk2rbJZdog2ELIcfWXVegMw1xB_jA6iKYlbiF-imGLZ2DnchucoRTZVzxPBnEtoE4uV72EbjCuanJO5ioOc3mnJsG8jO6lCXygAleyEhAt1tCrLHbDrZPd7es9oED1aCMMixHInOXxJGnlY2N-hophTU7iDqUCH5OeQfBtoLlesmYSjN2DeekmmYRE7qSu26T9hqXuTmGYNI-UopBzUSEZ62AyzYPEUZnxjfVDBg77qZFknLfk5JOGai4W3mAsdd1OM-YG960XlD-XGd0LBTF9FilQaDCJzR68TXO5US7SZRotfljD2iy7cH7HVfjcub7mxkbooFyXDUZERh4wF72qhi3yhOuRhtN8K-1Qp1c2vFfvy1Lqz9u-grdjvemYjPn44OnrM7vM4CQk_r1tlqdb4wLxCLVeplveZ-A9shL7U |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Utilizing+in+vitro+and+PBPK+tools+to+link+ADME+characteristics+to+plasma+profiles%3A+case+example+nifedipine+immediate+release+formulation&rft.jtitle=Journal+of+pharmaceutical+sciences&rft.au=Wagner%2C+Christian&rft.au=Thelen%2C+Kirstin&rft.au=Willmann%2C+Stefan&rft.au=Selen%2C+Arzu&rft.date=2013-09-01&rft.issn=1520-6017&rft.eissn=1520-6017&rft.volume=102&rft.issue=9&rft.spage=3205&rft_id=info:doi/10.1002%2Fjps.23611&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3549&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3549&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3549&client=summon |